What happened when Swissmedic joined FDA Oncology Center’s Project Orbis

FDA Oncology shared a post by The Lancet Oncology on X/Twitter:

“What happened when Swissmedic joined FDA Oncology Center’s Project Orbis? Submission gap and review time for oncology applications were significantly reduced, suggesting Orbis participation could lead to faster patient access to drugs.”

Quoting The Lancet Oncology’s post:

“Online First:
Effect of Project Orbis participation by the Swiss regulator Swissmedicon submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.”

Visit the article website.
Source: FDA Oncology/X and The Lancet Oncology/X